Paper Details

  1. Home
  2. Paper Details

Phase 1b/2 trial of tepotinib in sorafenib pretreated advanced hepatocellular carcinoma with MET overexpression.

Author: AssenatEric, BaroneCarlo, BerghoffKarin, BlancJean-Frédéric, BrunsRolf, DecaensThomas, FaivreSandrine, FasoloAngelica, GrandoVéronique, IacobellisAngelo, MerlePhilippe, RaymondEric, ScheeleJuergen, StraubJosef, TrojanJoerg, VillaErica, WermkeMartin

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

A Phase 1b/2 study of 66 patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression found that tepotinib was generally well tolerated and the recommended Phase 2 dose (RP2D) showed promising efficacy. The 12-week progression-free survival (PFS) was 63.3% in the tepotinib group, which was significantly greater than the predefined null hypothesis of ≤15%.
Paper Details　
Original Abstract of the Article :
BACKGROUND: This Phase 1b/2 study evaluated tepotinib, a highly selective MET inhibitor, in US/European patients with sorafenib pretreated advanced hepatocellular carcinoma (aHCC) with MET overexpression. METHODS: Eligible adults had aHCC, progression after ≥4 weeks of sorafenib, and, for Phase 2 o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292404/

データ提供：米国国立医学図書館（NLM）

Tepotinib: A New Weapon in the Fight Against Liver Cancer

Hepatocellular carcinoma (HCC), a type of liver cancer, can be a difficult opponent to conquer. This Phase 1b/2 study investigates the effectiveness of tepotinib, a highly selective MET inhibitor, in patients with advanced HCC who have progressed after treatment with sorafenib. The study found that tepotinib was generally well tolerated and showed promising efficacy in patients with MET overexpression, suggesting its potential as a valuable new treatment option for this challenging disease.

Tepotinib: A Potential Turning Point in Liver Cancer Treatment

This study, like a well-aimed arrow striking a target in the desert, highlights the potential of tepotinib as a promising new weapon against liver cancer. The findings suggest that tepotinib could offer a significant advantage for patients with MET overexpression, potentially extending their lives and improving their quality of life.

A Glimpse of Hope in the Desert of Liver Cancer

This research offers a ray of hope in the often-unforgiving desert of liver cancer. Tepotinib, a new targeted therapy, demonstrates promising efficacy for patients with MET overexpression, potentially providing a more effective and tolerable treatment option. This research underscores the importance of continued exploration and development of new therapeutic strategies for this challenging disease.

Dr.Camel's Conclusion

The fight against liver cancer can be a grueling and often futile battle. This study, like a camel caravan discovering a hidden spring in a barren desert, offers a potential lifeline for patients with MET overexpression. Tepotinib, a new targeted therapy, emerges as a promising weapon in the fight against this challenging disease, potentially providing a more effective and tolerable treatment option. This research reminds us that even in the vast and unforgiving landscape of cancer, new discoveries can offer hope and potentially lead to a more favorable outcome for patients.

Date :
  1. Date Completed 2021-12-10
  2. Date Revised 2023-11-07
Further Info :

Pubmed ID

33824476

DOI: Digital Object Identifier

PMC8292404

Related Literature

Article Analysis
・Effects of tepotinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.